---
schema_version: "secwatch.filing_event.v1"
accession: "0000914475-24-000180"
form_type: "8-K"
ticker: "NBIX"
cik: "0000914475"
company_name: "NEUROCRINE BIOSCIENCES INC"
filed_at: "2024-08-01T23:59:59+00:00"
generated_at: "2026-05-31T14:11:26.915751+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Neurocrine Q2 INGREZZA sales $580M (+32% YoY); raises FY guidance; CEO Gorman to retire Oct 11

## Summary
- INGREZZA Q2 net product sales $580M (+32% YoY); FY 2024 guidance raised to $2.25-$2.3B.
- GAAP net income $65M ($0.63 EPS); Non-GAAP net income $168.9M ($1.63 EPS), vs $125.7M ($1.25) YoY.
- CEO Kevin Gorman to retire Oct 11, 2024; succeeded by Kyle Gano, current Chief Business Development Officer.
- FDA granted Priority Review for crinecerfont in CAH; PDUFA Dec 29 (capsule) and Dec 30 (oral solution) 2024.
- Top-line Phase 2 data for NBI-'568 (schizophrenia) and luvadaxistat (CIAS) on track for Q3 2024.

## SEC filing metadata
- accession: 0000914475-24-000180
- form_type: 8-K
- ticker: NBIX
- cik: 0000914475
- company_name: NEUROCRINE BIOSCIENCES INC
- filed_at: 2024-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/914475/000091447524000180/0000914475-24-000180-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/914475/000091447524000180/nbix-20240801.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000914475-24-000180
- JSON: https://secwatch.observer/filing/0000914475-24-000180.json
- Plain text: https://secwatch.observer/filing/0000914475-24-000180.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.